ARTICLE | Clinical News
RGSH4K: Phase I started
November 16, 2015 8:00 AM UTC
Regeneus began the open-label, dose-escalation, Australian Phase I ACTIVATE trial to evaluate intradermal RGSH4K using 100, 250 or 500 ug streptavidin on weeks 1, 4 and 7 in up to 21 patients. ...